: Intellia Therapeutics stock gains on CRISPR treatment results

Intellia Therapeutics Inc. NTLA shares gained 6.4% premarket on Monday after the clinical stage genome-editing company announced new data from a trial of an investigational CRISPR-based therapy for hereditary angioedema. Patients treated with a single dose of the therapy, NTLA-2002, saw durable elimination of their attacks, according to Intellia data shared Sunday at the European Academy of Allergy and Clinical Immunology conference in Hamburg, Germany. Hereditary angioedema is a rare genetic disorder that can cause severe inflammatory attacks in organs and tissues.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.